Table 1.
Demographic Characteristics of the Patients at Baseline.*
| Characteristic | Ledipasvir–Sofosbuvir for 12 Wk (N = 335) |
|---|---|
| Median age (IQR) — yr | 52 (48–58) |
| Male sex — no. (%) | 276 (82) |
| Race — no. (%)† | |
| White | 203 (61) |
| Black | 115 (34) |
| Asian | 6 (2) |
| Other or unknown | 11 (3) |
| Median body-mass index (IQR)‡ | 27 (24–30) |
| HCV genotype — no. (%) | |
| 1a | 250 (75) |
| 1b | 77 (23) |
| 4 | 8 (2) |
| Median HCV RNA (IQR) — log10 IU/ml | 6.9 (6.3–7.2) |
| IL28B genotype — no. (%) | |
| CC | 81 (24) |
| CT | 185 (55) |
| TT | 69 (21) |
| Cirrhosis — no. (%) | 67 (20) |
| Median CD4+ cell count (IQR) — cells/µl | 628 (469–823) |
| Antiviral regimen — no. (%) | |
| Efavirenz–emtricitabine–tenofovir DF | 160 (48) |
| Raltegravir–emtricitabine–tenofovir DF | 146 (44) |
| Rilpivirine–emtricitabine–tenofovir DF | 29 (9) |
| HCV treatment history — no. (%) | |
| No previous treatment | 150 (45) |
| Previous treatment | 185 (55) |
*
DF denotes disoproxil fumarate, HVC hepatitis C virus, and IQR interquartile range.
†
Race was self-reported.
‡
The body-mass index is the weight in kilograms divided by the square of the height in meters.